A Comprehensive Supply Chain for Core Intermediates in Diabetes Treatment
March 6, 2026
End-to-end supply chain for anti-diabetic intermediates. Covering DPP-4, SGLT-2 inhibitors & GPR40 agonists. Stable, compliant, scalable.
Breaking Through: Tianming Pharmaceutical Achieves Commercial Production of Orforglipron Intermediates
In today’s era, breakthroughs in pharmaceuticals often depend on mastering complex chemical synthesis. Tianming Pharmaceutical is proud to announce a milestone achievement: the successful commercialization of orforglipron intermediates.
After years of relentless research, strategic problem-solving, and cross-functional collaboration, our team overcame the technical and logistical obstacles that once hindered the global production of this critical compound.
Today, we share our journey and capabilities with the global scientific community and industry partners.
Exploring Orforglipron Intermediates: Why They Matter
Orforglipron is a next-generation therapeutic drug gaining increasing attention in metabolic disorder research, whose synthesis relies on a complex network of intermediates.
These intermediates typically feature unstable molecular structures and stringent production conditions, posing long-standing challenges for manufacturers. A minor error in temperature control, catalyst selection, or purification protocols could render an entire batch of the process ineffective, making scalable production a long-sought-after goal for chemists worldwide.
At Tianming Pharmaceuticals, we recognized early on that mastering the intermediates for Gliclazide requires not only chemical expertise but also redefining the possibilities of API production.
From Lab to Scale: The Path to Commercialization
- Deconstructing Complexity
Our R&D team first analyzed the molecular structure of Gliclazide, identifying three core intermediates as key pathways.
- Overcoming Technical Challenges
Catalyst Optimization: Traditional palladium catalysts were inefficient for synthesizing intermediates. After multiple iterations, our team pioneered a catalyst system that reduced reaction time by 60% while maintaining a 99% ee value (enantiomeric excess).
Stability Breakthrough: We designed a proprietary solvent system to inhibit hydrolysis, significantly reducing degradation rates during post-processing.
Process Enhancement: By integrating continuous flow chemistry technology, we increased yield from 68% (batch) to 89% at a 10x scale.
- Regulatory and Quality Milestones
Every kilogram of orforglipron intermediates produced at our cGMP-certified facility undergoes the following processes:
Heavy metal screening via ICP-MS
Residual solvent testing in accordance with ICH Q3C guidelines
Learn about the Orforglipron Intermediate Series: Now Available for Large-Scale Production
Below is our commercially validated product portfolio to help accelerate your drug development:
Name | Chemical Information | Cas.NO |
1-(cyanomethyl)-5-[(4S)-2,2-dimethyloxan-4-yl]-N-methyl-N-phenylin-dole-2-carboxamid | Chemical Formula: C25H27N3O2 | 2212021-80-0 |
5-((S)-2,2-dimethyltetrahydro-2H-pyran-4-yl)-1-((1S,2S)-1-((Z)-N’-hydroxycarbamimidoyl)-2-methylcyclopropyl)-N-methyl-N-phenyl-1H-indole-2-carboxamide | Chemical Formula: C28H34N4O3 | 3047556-95-3 |
5-[(4S)-2,2-dimethyloxan-4-yl]-N-methyl-1-[(1 S,2S)-2-methyl-1-(5-oxo-4H-1,2,4-oxadiazol-3-yl)cyclopropyl]-N-phenylindole-2-carboxamide | Chemical Formula: C29H32N4O4 Molecular Weight: 500.60 | 2212021-82-2 |
5-[(S)-2,2-Dimethyltetrahydro-2H-pyran-4-yl]-1-[(1S,2S)-2-methyl-1-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)cyclopropyl]-1H-indole-2-carboxylic Acid | Chemical Formula: C22H25N3O5 Molecular Weight: 411.46 | 2212021-83-3 |
tert-butyl (S)-2-(4-fluoro-3,5-dimethylphenyl)-4-methyl-3-(2-oxo-2,3-dihydro-1H-imida-zol-1-yl)-2,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxylat | Chemical Formula: C23H28FN5O3 Molecular Weight: 441.51 | 2212021-61-7 |
5-bromo-4-fluoro-1-methyl-1H-indazole | Chemical Formula: C8H6BrFN2 Molecular Weight: 229.05 | 1784678-61-0 |
tert-butyl (4S)-2-(4-fluoro-3,5-dimethylphenyl)-3-[3-(4-fluoro-1-methylindazol-5-yl)-2-oxoimidazol-1-yl]-4-methyl-6,7-dihydro-4H-pyrazolo[4,3-c]pyridine-5-carboxylate | Chemical Formula: C31H33F2N7O3 Molecular Weight: 589.65 | 2212022-55-2 |
(S)-1-(4-fluoro-2-methyl-2H-indazol-5-yl)-3-(2-(4-fluoro-3,5-dimethylphenyl)-4-methyl-4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridin-3-yl)-1H-imidazol-2(3H)-one | Chemical Formula: C26H25F2N7O Molecular Weight: 489.53 | 2212022-56-3 |
Orforglipron | Chemical Formula: C48H48F2N10O5 Molecular Weight: 882.97 | 2212020-52-3 |
Orforglipron hemicalcium hydrate | Chemical Formula: C48H48F2N10O5.1/2Ca.H2O Molecular Weight: 921.02 | 3008544-96-2 |
Complete specifications and production license (COA) are available upon request.
Looking Ahead: Working Together
Tianming Pharmaceutical is now inviting pharmaceutical companies, contract research organizations (CROs), and research institutions to utilize our orforglipron intermediates for the following purposes:
- Preclinical API synthesis
- Generic drug formulation
- Process validation studies
- Custom intermediate R&D
We invite all interested parties to contact us for more information about orforglipron intermediates. Whether you are a pharmaceutical company in need of these key compounds or a researcher seeking collaboration, we are eager to connect with you and explore potential partnerships.
Contact us immediately Email: sunqian0123@gamil.com
Related Blogs
CDMO vs. Direct Manufacturer: Which Model Fits Your API Strategy?
March 3, 2026
Drawing from on-the-ground experience in China’s top pharma clusters, this guide cuts through the jargon to reveal when to partner for complex innovation and when to buy from the workhorses of mature production.
Case Study: Improving Yield & Purity Through Route Optimization
February 27, 2026
This case study, based on publicly available academic literature and patents, focuses on the application of synthetic route optimization in improving the yield and purity of Active Pharmaceutical Ingredients (APIs).